statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 6,600 shares, a...

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.56...

Acasti Pharma (NASDAQ:ACST) Stock Passes Above Two Hundred Day Moving Average of $2.56

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Acasti Pharma Inc. (NASDAQ:ACST) Sees Large Growth in Short Interest

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.38...

Acasti Pharma (NASDAQ:ACST) Stock Price Crosses Above Two Hundred Day Moving Average of $2.38

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Up 20.4% in January

Acasti Pharma (NASDAQ:ACST  Get Free Report) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter...

Acasti Pharma (NASDAQ:ACST) Announces Quarterly  Earnings Results, Beats Estimates By $0.02 EPS

Acasti Pharma GAAP EPS of -$0.21

Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial...

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Acasti Pharma initiated with bullish view at Craig-Hallum

Acasti Pharma announces poster detailing its GTX-104 STRIVE-ON Trial

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Volume	2,583.00
52-Wk High	$3.84
52-Wk Low	$1.72

ACST Acasti Pharma Inc - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals